December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Cell Therapy: A Cryopreserved Immortalized Human RPE Cell Line Rescues Visual Function in the RCS Rat
Author Affiliations & Notes
  • JJ Crouzet
    Neurotech SA Evry France
  • E Clérin
    Neurotech SA Evry France
  • PJ Coffey
    Department of Psychology University of Sheffield Sheffield United Kingdom
  • A Darmon
    Neurotech SA Evry France
  • S Brimicombe-Lefevre
    Neurotech SA Evry France
  • A Zerbib
    Neurotech SA Evry France
  • L Hetherington
    Department of Psychology University of Sheffield Sheffield United Kingdom
  • L Vignais
    Neurotech SA Evry France
  • S Timsit
    Neurotech SA Evry France
  • M Neuner-Jehle
    Neurotech SA Evry France
  • Footnotes
    Commercial Relationships    J.J. Crouzet, Neurotech SA E; E. Clérin, Neurotech SA E; P.J. Coffey, Neurotech SA F; A. Darmon, Neurotech SA E; S. Brimicombe-Lefevre, Neurotech SA E; A. Zerbib, Neurotech SA E; L. Hetherington, Neurotech SA F; L. Vignais, Neurotech SA E; S. Timsit, Neurotech SA E; M. Neuner-Jehle, Neurotech SA E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3447. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JJ Crouzet, E Clérin, PJ Coffey, A Darmon, S Brimicombe-Lefevre, A Zerbib, L Hetherington, L Vignais, S Timsit, M Neuner-Jehle; Cell Therapy: A Cryopreserved Immortalized Human RPE Cell Line Rescues Visual Function in the RCS Rat . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3447.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Neurotech S.A. is developing cell-based therapies for the treatment of ophthalmic disorders with a special interest in retinal degenerations. One of the company's core technologies consists of producing immortalized human retinal pigment epithelium (RPE) cell lines which can be safely used for RPE cell replacement therapies in humans. Such cell lines present many advantages over primary RPE cells; they can be thoroughly characterized and tested for microbiological safety. Moreover, extensive pharmacological studies can be performed on a standardized product that would be used in the clinic. Well-characterized human RPE cell lines have recently been described to be efficient in rescuing photoreceptors in the dystrophic Royal College of Surgeons (RCS) rat model when they were freshly harvested from culturesa. Here we investigated whether thawed immortalized human RPE cells (NTC-200 cells) could be used instead of cells directly harvested from cultures. Methods: Three-week-old pigmented dystrophic RCS rats were treated under general anesthesiab by a unilateral injection of 2x105 thawed NTC-200 cells (2 µl) into the temporal superior subretinal space using a trans-scleral approach. Sham-treated dystrophic RCS rats received a unilateral subretinal injection of 2 µl graft medium. At the age of 8 and 12 weeks, all treated rats were subjected to optokinetic reflex testings using the spatial grating frequency of 0.5 cycles/degreec. At the age of 12 weeks, all treated rats were sacrificed for histology and photoreceptor nuclei counting. Results: A significant preservation of visual function was found in animals grafted with thawed NTC-200 cells. Conclusion: The presented results contribute to the concept of using cryopreserved immortalized human RPE cell lines as a bioactive clinical product. a Lund et al. (2001) Proc. Natl. Acad. Sci. USA 98(17):9942-9947, Coffey et al. (2001) Nat. Neurosci., in press. b All animal experiment procedures conform to NIH guidelines. c Cowey & Franzini (1979) Exp. Brain Res. 35,443-455.

Keywords: 567 retinal pigment epithelium • 308 age-related macular degeneration • 607 transplantation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.